WASHINGTON, Mar 19, 2008 (UPI via COMTEX) -- The U.S. Food and Drug
Administration has issued a safety alert for Spiriva, a drug used to treat
certain symptoms of chronic obstructive pulmonary disease.
The FDA said ongoing safety monitoring conducted by the drug's manufacturer --
the Boehringer Ingelheim Corp. -- has identified a possible increased risk of
stroke in patients who take Spiriva to treat bronchospasm associated with COPD.
An analysis of safety data from 29 placebo controlled clinical studies estimates
the risk of stroke are 8 patients per 1,000 patients treated for one year with
Spiriva, and 6 patients per 1,000 patients treated for one year with placebo.
That, the FDA said, means the estimated excess risk of any type of stroke due to
Spiriva is 2 patients for each 1,000 patients using Spiriva during a one year
period.
The FDA said it is working with Boehringer Ingelheim to further evaluate the
potential association between Spiriva and stroke. The agency said patients with
questions about the new information should not stop taking Spiriva before
talking with their physician.
URL: www.upi.com
Copyright 2008 by United Press International